Literature DB >> 15308295

Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans.

Christopher C T Smith1, D John Betteridge.   

Abstract

The circulation constitutes a potential source of the beta-amyloid (A beta) protein deposited cerebrally in Alzheimer's disease (AD). Cardiovascular risk factors, including hyperlipidaemia, may be involved in the pathogenesis of AD. Plasma A beta 40 was measured by radioimmunoassay in normal and hyperlipidaemic subjects with the aim of determining if plasma lipid content and/or age correlated with circulating A beta 40 concentration. Plasma A beta 40 levels in hyperlipidaemics were elevated by 20.3% compared to normal subjects. A beta 40 did not correlate with plasma lipids in normal subjects. Age, however, correlated positively with A beta 40 in these individuals and with total cholesterol, low-density lipoprotein (LDL) and triglycerides. No correlations were observed in hyperlipidaemic patients or when the data for the two groups were combined. These data are consistent with ageing, the primary risk factor for AD, but not hyperlipidaemia influencing circulating A beta 40 levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308295     DOI: 10.1016/j.neulet.2004.05.081

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver.

Authors:  Chihiro Tamaki; Sumio Ohtsuki; Takeshi Iwatsubo; Tadafumi Hashimoto; Kaoru Yamada; Chiori Yabuki; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 2.  Insulin, cognition, and dementia.

Authors:  Brenna Cholerton; Laura D Baker; Suzanne Craft
Journal:  Eur J Pharmacol       Date:  2013-09-23       Impact factor: 4.432

Review 3.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.

Authors:  Suzanne Craft
Journal:  Arch Neurol       Date:  2009-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.